Global study aims to predict outcomes for rare skin lymphoma patients
NCT ID NCT02848274
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting medical information from 2000 people with advanced mycosis fungoides or Sézary syndrome, two rare types of skin lymphoma. The goal is to create a tool that helps doctors predict which patients are at higher or lower risk, so they can tailor treatments more effectively. Participants are not given any experimental treatment—only standard care is observed and recorded.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
Hospital Italiano de Buenos Aires
RECRUITINGBuenos Aires, Argentina
-
Peking University First Hospital
RECRUITINGBeijing, China
-
Peter MacCallum Cancer Center,
RECRUITINGMelbourne, Australia
-
Stanford University, School of Medicine
RECRUITINGPalo Alto, California, 94305, United States
-
The University of Tokyo
RECRUITINGTokyo, Japan
-
University Hospitals Birmingham
RECRUITINGBirmingham, United Kingdom
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
-
University of Pittsburg
RECRUITINGPittsburgh, Pennsylvania, 15260, United States
-
University of Sao Paulo Medical School
RECRUITINGSão Paulo, Brazil
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
-
University of Utah Hospital
RECRUITINGSalt Lake City, Utah, 84132, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin gel targets immune signals in rare lymphoma
- Supercharged immune cells take aim at cancer and viruses in one shot
- Could an ALS drug clear the fog of chemo brain?
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Combination therapy aims to boost response in rare skin cancers
- Gut bacteria may hold key to chemo side effects